BIOLOGIC AGENTS FOR PSORIASIS
Introduction
Since the late 1990s, the use of biologics for psoriasis has been showcased in the dermatology literature and in educational meetings. Most of the literature has focused on the safety and efficacy data generated from clinical trials. The aim of this issue is to take this discussion one step further and examine the incorporation of these agents successfully into clinical practice.
Combining Traditional Agents and Biologics for the Treatment of Psoriasis
A review of the literature, plus our personal experience in using combinations of traditional agents and biologics, is presented.
Psoriatic Arthritis and Psoriasis: Need for a Multidisciplinary Approach
Because dermatologists are on the front-line of psoriasis management, we are perfectly poised to identify and help improve care for patients who suffer from both psoriasis and psoriatic arthritis.
The Impact of Biologics on the Quality of Life of Psoriasis Patients and the Economics of Psoriasis Care
Rapid advancements in fundamental immunological mechanisms have led to the development of new targets for treating psoriasis.
Potential Future Therapies for Psoriasis
Much of the recent dermatology literature on new therapies has focused on large molecules, protein-based fusion proteins, and monoclonal antibodies; however, other compounds have not been neglected.